The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate,…
Featured Articles
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) was a common clinical manifestation among people carrying a mutation in the TTR gene called p.Ala117Ser, according to a study conducted in Thailand. Similar to findings from other studies in parts of Asia, p.Ala117Ser was the most common mutation among people with transthyretin…
Homes and landmarks across the U.S. and other countries will once again light up in red throughout March for Amyloidosis Awareness Month as the…
Signs of more advanced heart disease and the presence of nerve involvement are associated with a higher risk of worse outcomes, including heart failure, hospitalization…
An easily accessible diagnostic test called pain-related evoked potentials with concentric electrodes (PrEP-CE) may help detect the onset of hereditary transthyretin amyloidosis with polyneuropathy…
Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) across…
Newly diagnosed? Start your journey here.
Need to know
Becoming educated and informed about FAP is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
Personal experiences
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your FAP journey.
Treatment
There is no cure for FAP yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.